Celularity Inc. filed SEC Form 8-K: Other Events
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events
The Board of Directors of Celularity Inc., or Celularity, established that the 2024 Annual Meeting of Stockholders of Celularity, or the 2024 Annual Meeting, will be held on Thursday, December 19, 2024. The record date for the determination of Celularity stockholders entitled to receive notice of and to vote at the 2024 Annual Meeting was the close of business on Friday, November 8, 2024. Because the date of the 2024 Annual Meeting differs by more than thirty (30) days from the anniversary date of the 2023 Annual Meeting of Stockholders, which was held on June 14, 2023, Celularity is hereby providing notice, pursuant to Rule 14a-5(f) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, of the deadlines for any stockholder proposals pursuant to Rule 14a-8 under the Exchange Act and for any stockholder nomination or proposal outside of Rule 14a-8 via this Form 8-K.
To be considered for inclusion in this year’s proxy materials for the 2024 Annual Meeting, stockholder proposals must be submitted in writing by the close of business on November 18, 2024 to Celularity’s Corporate Secretary at Celularity’s principal offices at 170 Park Avenue, Florham Park, NJ 07932. In addition to complying with this deadline, stockholder proposals intended to be considered for inclusion in the proxy materials for the 2024 Annual Meeting must also comply with Celularity’s bylaws and all applicable rules and regulations promulgated by the Securities and Exchange Commission under the Exchange Act. Additionally, any stockholder who intends to submit a proposal regarding a director nomination or any other matter of business at the 2024 Annual Meeting not to be included in Celularity’s proxy materials for the 2024 Annual Meeting, must also ensure that notice of any such proposal (including any additional information specified in Celularity’s bylaws) is received by the Corporate Secretary at Celularity’s principal executive offices by the close of business on November 18, 2024.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CELULARITY INC. | |||
| Date: | November 8, 2024 | By: | /s/ Robert J. Hariri |
| Robert J. Hariri, M.D., Ph.D. | |||
| Chairman and CEO | |||